Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche : Arthritis Drug Meets Key Endpoint in Covid-19 Pneumonia Study

share with twitter share with LinkedIn share with facebook
09/18/2020 | 07:14am EDT

By Colin Kellaher

 

Roche Holding AG's Genentech unit on Friday said a Phase 3 study of its arthritis drug Actemra met its primary endpoint of reducing the likelihood of the need for mechanical ventilation in hospitalized patients with pneumonia associated with Covid-19.

Genentech said patients who received Actemra plus standard of care were 44% less likely to progress to mechanical ventilation or death compared to patients who received placebo plus standard of care.

The study showed that the cumulative proportion of patients who progressed to mechanical ventilation or death by day 28 was 12.2% in the Actemra arm, compared with 19.3% in the placebo arm, the company said, adding that there were no new safety signals for the drug.

In late July, Genentech said a separate Phase 3 study of Actemra missed its primary endpoint of improved clinical status in adults hospitalized with severe Covid-19 associated pneumonia.

Actemra works to suppress the overreaction of a person's immune system by blocking proteins called interleukin-6, which trigger the body's inflammatory response. Researchers believe that the overreaction of the immune system might be causing the most severe damage to Covid-19 patients, and that drugs that stop this response might ease some of the most severe symptoms.

Genentech said it plans to share the latest data with the U.S. Food and Drug Administration and other health authorities around the world.

 

--Brianna Abbott contributed to this article.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 


share with twitter share with LinkedIn share with facebook
All news about ROCHE HOLDING AG
03:54pROCHE : COVID SCIENCE-COVID-19 complication rates far higher than for flu; open ..
RE
01:36pPROTHENA : Shares Rise 7% on Prasinezumab Study With Roche
DJ
09:22aPTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
DJ
07:57aROCHE : and Prothena will Advance Prasinezumab into Late-Stage Clinical Developm..
AQ
10/20ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/20Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..
AQ
10/19ROCHE : Genentech Announces Full FDA Approval for Venclexta Combinations for Acu..
AQ
10/19ROCHE HOLDINGS AG : JP Morgan reaffirms its Buy rating
MD
10/19ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
AQ
10/19ROCHE : announces full FDA approval for Venclexta combinations for acute myeloid..
PU
More news
Financials
Sales 2020 60 427 M 66 754 M 66 754 M
Net income 2020 14 685 M 16 223 M 16 223 M
Net cash 2020 3 204 M 3 539 M 3 539 M
P/E ratio 2020 17,7x
Yield 2020 3,10%
Capitalization 256 B 283 B 283 B
EV / Sales 2020 4,18x
EV / Sales 2021 3,85x
Nbr of Employees 97 735
Free-Float 83,6%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 379,15 CHF
Last Close Price 299,15 CHF
Spread / Highest target 47,8%
Spread / Average Target 26,7%
Spread / Lowest Target 3,63%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG-2.21%289 156
JOHNSON & JOHNSON-0.90%380 575
PFIZER INC.-3.52%208 327
MERCK & CO., INC.-13.94%197 964
NOVARTIS AG-15.38%188 853
NOVO NORDISK A/S16.64%166 534